When facing thousands of listed company announcements every day, which ones should you read? What are the key points to take away from the dozens or hundreds of pages of material announcements? Are the many professional terms in the announcements bullish or bearish? Check out Caixin's "Quick Read Announcement" column, where our reporters across the country will provide you with accurate, fast and professional interpretations on the night of the announcement.

According to Cailian Press on August 28th, due to changes in the external market environment and internal business adjustments, apichope pharmaceutical (300723.SZ), which was just punished by the National Medical Insurance Bureau for bid-rigging, saw a decrease in revenue and net income in the first half of the year. This is the company's fourth consecutive quarter of declining performance.

Tonight, apichope pharmaceutical released its semi-annual report. The company achieved a revenue of 0.913 billion yuan in the first half of the year, a year-on-year decrease of 27.90%; The net income attributable to shareholders of the listed company was 46.4583 million yuan, a year-on-year decrease of 77.33%.

Looking at the different business segments, apichope pharmaceutical saw a decline in revenue and gross margin in the first half of the year for all three major business segments. Among them, the revenue of pediatric drugs was 0.502 billion yuan, a decrease of 36.25% year-on-year, and the gross margin decreased by 3.35 percentage points to 82.48% year-on-year. The revenue of chronic disease drugs was 0.317 billion yuan, a decrease of 13.64% year-on-year, and the gross margin decreased by 16.56 percentage points to 67.23% year-on-year. The revenue of other business segments was 0.094 billion yuan, a decrease of 15.90% year-on-year, and the gross margin decreased by 31.29% year-on-year.

In terms of pediatric drugs, apichope pharmaceutical has a total of 25 registered approvals, a decrease of 2 compared to the same period last year. The treatment scope covers the entire age range of children from 0 to 14 years old, and is used to treat common diseases such as children's influenza and colds. It has 31 pediatric drug projects in development. The number of registered approvals for chronic disease drugs increased to 63, and there are 36 projects in development, covering cardiovascular and cerebrovascular diseases, urinary system diseases, and other diseases.

In addition to the decline in performance, apichope pharmaceutical also committed violations during the centralized procurement process. On July 28th, apichope pharmaceutical announced that it had received a breach of contract notice from the National Joint Drug Procurement Office. It was found to have engaged in irregularities during the bidding process for the centralized volume-based procurement of bromofloxine hydrobromide injection. It was ordered to return 0.266 billion yuan to the purchasing party and was also suspended from participating in national procurement qualifications for 6 months. On August 21st, the National Medical Insurance Bureau's official WeChat account reported that apichope pharmaceutical had returned the medical insurance funds lost, proactively lowered the price of bromofloxine hydrobromide injection, and voluntarily reduced the price of 3-4 other drugs.